Thymogen

✓Key benefits

📈What to expect

Based on community reports and published research. Individual results vary significantly.

💊Dosing protocols

Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.

Overview

Thymogen was developed at the Institute of Bioregulation and Gerontology in Saint Petersburg as part of the Khavinson peptide bioregulator program. It is one of the simplest bioactive peptides known: just two amino acids (glutamic acid and tryptophan). In Russian medicine, it is registered as a pharmaceutical for immune deficiency states, chronic infections, and post-surgical immune recovery. It is available as both injectable and intranasal formulations. Western peer-reviewed data is limited, but Russian clinical studies report effects on T-cell differentiation and immune function restoration.

⚙️How it works

The exact mechanism is not fully characterised in Western literature. Russian researchers propose that the Glu-Trp sequence interacts with thymic epithelial cells to promote T-cell maturation and differentiation. It is reported to normalise the CD4/CD8 ratio, enhance thymic output of naive T-cells, and modulate cytokine profiles toward balanced Th1/Th2 responses.

⚡Side effects

📅Research history

References

1. [1]Khavinson VK, Morozov VG. 'Peptides of pineal gland and thymus prolong human life.' Neuroendocrinology Letters, 2003.

Frequently asked questions

Related peptides